KCTD3 Antibody [DyLight 405]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-44277V
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunoprecipitation, Western Blot (Negative)
Label
DyLight 405 (Excitation = 400 nm, Emission = 420 nm)
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
The epitope recognized by this antibody maps to a region between residue 675 to 725 of human BTB/POZ domain-containing protein KCTD3 using the numbering given in entry Q9Y597.2 (GeneID 51133).
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for KCTD3 Antibody [DyLight 405]
Application
Recommended Usage
Immunoprecipitation
Optimal dilutions of this antibody should be experimentally determined.
Western Blot (Negative)
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: KCTD3
Alternate Names
BTB/POZ domain-containing protein KCTD3, potassium channel tetramerisation domain containing 3, renal carcinoma antigen NY-REN-45
Gene Symbol
KCTD3
Additional KCTD3 Products
Product Documents for KCTD3 Antibody [DyLight 405]
Product Specific Notices for KCTD3 Antibody [DyLight 405]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...